Stem Cell Therapeutics raises $33M in private placement


Stem Cell Therapeutics (SCTPF) raises $33M in gross proceeds through a private placement of 157.1M in common and preferred units (each with a 3/4 warrant to purchase an additional common share at $0.28) at a price of $0.21/unit.

The round was led by a "prominent U.S. healthcare fund," with participation from 7 other funds.

Funds will be used for IND-enabling studies, manufacturing, and phase I clinical trials of the company's CD47 cancer stem cell program.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs